What is the current valuation of the US preclinical CRO market?

The market valuation was $1379.7 Million in 2024. Read More

What is the projected market size for the US preclinical CRO market by 2035?

The projected valuation for 2035 is $2517.69 Million. Read More

What is the expected CAGR for the US preclinical CRO market during the forecast period 2025 - 2035?

The expected CAGR is 5.62%. Read More

Which companies are considered key players in the US preclinical CRO market?

Key players include Charles River Laboratories, Covance, PRA Health Sciences, and others. Read More

How does the oncology segment perform in the US preclinical CRO market?

The oncology segment had a valuation range of $400.0 Million to $800.0 Million. Read More

What is the valuation range for toxicology testing in the US preclinical CRO market?

Toxicology testing had a valuation range of $450.0 Million to $850.0 Million. Read More

What is the valuation range for in vivo studies in the US preclinical CRO market?

In vivo studies had a valuation range of $400.0 Million to $750.0 Million. Read More

How does the neurology segment compare to other therapeutic areas in the US preclinical CRO market?

The neurology segment had a valuation range of $300.0 Million to $600.0 Million, indicating substantial market interest. Read More

US Preclinical CRO Market

Q: What are the main service types offered in the US preclinical CRO market?

Main service types include Biologics Testing, Small Molecule Testing, Toxicology Testing, and Pharmacology Testing. Read More

Q: Which end users are prominent in the US preclinical CRO market?

Prominent end users include Pharmaceutical Companies, Biotechnology Companies, and Academic Institutions. Read More

US Preclinical CRO Market Research Report: Size, Share, Trend Analysis By Service Type (Biologics Testing, Small Molecule Testing, Toxicology Testing, Pharmacology Testing), By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases), By Validation Type (In Vivo Studies, In Vitro Studies, Comparative Studies, Regulatory Studies) and By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.62%

2024 Market Size

$ 1,379.7 Million

2035 Market Size

$ 2,517.69 Million

Healthcare Services ● Updated April 2026 Report ID: MRFR/HS/47586-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Service Type (USD Million)
  1. 4.1.1 Biologics Testing
  2. 4.1.2 Small Molecule Testing
  3. 4.1.3 Toxicology Testing
  4. 4.1.4 Pharmacology Testing
2. 4.2 Chemicals and Materials, BY Therapeutic Area (USD Million)
  1. 4.2.1 Oncology
  2. 4.2.2 Neurology
  3. 4.2.3 Cardiology
  4. 4.2.4 Infectious Diseases
3. 4.3 Chemicals and Materials, BY Validation Type (USD Million)
  1. 4.3.1 In Vivo Studies
  2. 4.3.2 In Vitro Studies
  3. 4.3.3 Comparative Studies
  4. 4.3.4 Regulatory Studies
4. 4.4 Chemicals and Materials, BY End User (USD Million)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Biotechnology Companies
  3. 4.4.3 Academic Institutions
  4. 4.4.4 Research Organizations
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Charles River Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Covance (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 PRA Health Sciences (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Eurofins Scientific (LU)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Medpace (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Wuxi AppTec (CN)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Syneos Health (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 KCR (PL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pharmaron (CN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY SERVICE TYPE
3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA
4. 6.4 US MARKET ANALYSIS BY VALIDATION TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY VALIDATION TYPE, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY VALIDATION TYPE, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY SERVICE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  3. 7.2.3 BY VALIDATION TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Preclinical CRO Market Segmentation

US Preclinical CRO Market By Service Type (USD Million, 2025-2035)

Biologics Testing
Small Molecule Testing
Toxicology Testing
Pharmacology Testing

US Preclinical CRO Market By Therapeutic Area (USD Million, 2025-2035)

Oncology
Neurology
Cardiology
Infectious Diseases

US Preclinical CRO Market By Validation Type (USD Million, 2025-2035)

In Vivo Studies
In Vitro Studies
Comparative Studies
Regulatory Studies

US Preclinical CRO Market By End User (USD Million, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Academic Institutions
Research Organizations

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”